This week, I am sharing some basic science that reminds us that nothing about CLL is simple and that drugs nearly always have unintended and often unexpected consequences.
I explain the importance of a recent article from Nature: P13Kδ (phosphatidylinositol 3-kinase δ) blockade increases genomic instability in B cells where we learn how the tremendous therapeutic benefit of a drug may also be linked to potential concerns. You can read my summary and link to the abstract from Nature here: cllsociety.org/2017/03/p13-...
It’s a tough article to get through, but it has many possible implications.
Although not widely commented upon until recently, it is interesting that BTK's like Ibrutinib have some P13K effect. Combining this information with the potential genomic toxicity of P13K inhibition causes me to wonder if Acalabrutinib (which blocks far fewer kinases) might have less or none of this effect.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Optical Genome Mapping: a promising new tool to assess genomic complexity - Part Two
